METABOLIC & WEIGHT RESEARCH / MATRIX
Three Peptides, Three Evidence Tiers
MOTS-c, semaglutide, and tesamorelin lined up on mechanism, evidence depth, regulatory status, and the one caution that matters most for each.
The short version
This page lines up MOTS-c, semaglutide, and tesamorelin on the dimensions that actually determine how much weight a claim about any of them can bear: what mechanism each works through, how much of that mechanism has been tested in humans versus only in cells or animals, what (if anything) a regulator has approved, and the single most important caution for each. The honest headline is that these three compounds are nowhere near the same stage of evidence. Semaglutide has the deepest human trial record of the three by a wide margin. Tesamorelin has one solid, narrow approval. MOTS-c has essentially no human intervention data at all. Grouping them under 'metabolic research peptides' describes what they are studied for, not how well-established any given claim about them is. Nothing on this page is a recommended dose.
The comparison matrix
| Dimension | MOTS-c | Semaglutide | Tesamorelin |
|---|---|---|---|
| Peptide class | Mitochondrial-derived peptide (MDP); AMPK/CK2-linked signaling peptide | GLP-1 receptor agonist (incretin mimetic) | GHRH analogue (growth-hormone-axis stimulator) |
| Human evidence base | No completed human intervention trials; one observational cohort [2] | Large RCTs across obesity, diabetes, CVD, CKD, tens of thousands of participants [6][7][8][9][12] | RCTs in one population (HIV-associated lipodystrophy), several hundred participants total [13][15][17] |
| Most-studied in | Skeletal muscle glucose handling, exercise physiology, aging (mouse/cell) | Type 2 diabetes, obesity, cardiovascular and kidney outcomes | HIV-associated lipodystrophy (visceral fat, hepatic fat) |
| Administration studied | No standardized human route; rodent doses only [3] | Once-weekly subcutaneous injection; once-daily oral tablet | Once-daily subcutaneous injection |
| Regulatory status | Not approved; sold only as a research chemical | FDA-approved (multiple indications) | FDA-approved (one indication: HIV-associated lipodystrophy) |
| Key caution | No human dosing or safety data exist at all [3] | Real, well-characterized GI and biliary-disease signals; boxed thyroid warning based on rodent data [10][12] | Effect reverses on stopping; approval does not extend beyond its tested population [17] |
Mechanism
The three compounds do not share a mechanism, which is worth stating plainly since they are grouped together only by research theme. Semaglutide activates the GLP-1 receptor, mimicking a gut hormone to affect insulin, glucagon, gastric emptying, and central appetite circuits [11]. Tesamorelin activates the GHRH receptor on the pituitary, stimulating the body's own growth-hormone pulses rather than supplying a hormone directly, with downstream effects on IGF-1 and visceral-fat lipolysis [16]. MOTS-c works through a different system entirely — activating AMPK via the folate cycle and directly binding casein kinase 2, with effects concentrated in skeletal muscle and, under stress, in the cell nucleus [1]. Three distinct pharmacologies, not three variations on one theme.
Human evidence base
This is where the three separate most sharply. Semaglutide's evidence spans multiple large randomized trials — from roughly 2,000 to more than 17,000 participants — across weight management, cardiovascular outcomes, kidney outcomes, and a head-to-head efficacy comparison [6][7][8][9][12]. Tesamorelin's evidence is real but narrower: several hundred participants total across its pivotal trials, all within HIV-associated lipodystrophy, plus a small mechanistic study in healthy volunteers [13][15][16][17]. MOTS-c's human evidence, by contrast, is a single observational cohort of 94 hemodialysis patients measuring naturally occurring peptide levels — not a treatment trial of any kind [2]. Everything else said about MOTS-c in humans is inference from mouse and cell data.
Regulatory status
Semaglutide and tesamorelin are both FDA-approved, but at very different scales. Semaglutide carries approvals spanning type 2 diabetes, chronic weight management, cardiovascular-risk reduction, and (as of 2025) metabolic liver disease. Tesamorelin carries exactly one approval — reducing excess visceral fat in HIV-associated lipodystrophy [14] — and no other indication. MOTS-c has no regulatory approval of any kind and is sold exclusively as a research chemical, with supplier-dependent purity and identity that is not subject to pharmaceutical oversight. Approval status is not a proxy for how broadly a compound's evidence generalizes; tesamorelin's single approval is narrower than casual references to it as an 'approved peptide' tend to suggest.
Key caution
For semaglutide, the defining caution is that its well-documented gastrointestinal and gallbladder-disease signals, and a boxed thyroid warning resting on rodent (not human) tumor data, come packaged with genuinely strong efficacy evidence — the caution is real, but so is the benefit data, and neither should be used to wave away the other [10][12]. For tesamorelin, the defining caution is scope: its trial-tested effect reverses within weeks of stopping and applies to one specific population, so its use in other contexts is inference dressed as established fact [17]. For MOTS-c, the defining caution is the most basic one of all — there is no human safety or dosing data to caution about specifically, because there is no human intervention trial to have generated it [3]. Reading the three together, the pattern is not 'safe versus risky' but 'known versus unknown to very different degrees.'